Frazier Life Sciences Public Fund, L.P. 13D and 13G filings for Lexeo Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-13 5:33 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Frazier Life Sciences Public Fund, L.P. | 3,698,271 5.100% | 624,804 (+20.33%) | Filing |
| 2025-08-14 1:40 pm Sale | 2025-06-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Frazier Life Sciences Public Fund, L.P. | 3,073,467 5.700% | -2,427,345 (-44.13%) | Filing |
| 2025-06-04 4:51 pm Purchase | 2025-05-28 | 13G | LEXEO THERAPEUTICS INC LXEO | Frazier Life Sciences Public Fund, L.P. | 5,500,812 9.900% | 5,500,812 (New Position) | Filing |